CTRI/2022/08/044867
Completed
N/A
A Proof-of-Concept, Safety and Efficacy Study of SkinQ GlowBright Wonder Mask in Healthy Human Subjects and withadequate representation of varied skin types (Normal, Oily,Dry, Combined, and Sensitive skin).
Health Q Life Sciences Private Limited0 sites38 target enrollmentTBD
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Health Q Life Sciences Private Limited
- Enrollment
- 38
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Age: 18 to 55 years (both inclusive) old at the time of consent.
- •2\) Sex: Healthy adult males and non\-pregnant/non\-lactating females.
- •3\) Subject with normal Fitzpatrick skin type III to VI (Human skin colour determination scale).
- •4\) Females of childbearing potential must have a self\-reported negative urine pregnancy test.
- •5\) Subjects are generally in good general health as determined from recent medical history.
- •6\) Subjects with visibly tanned skin determine by a dermatologist or dermatologist trained evaluator.
- •7\) The subject does not have any previous history of adverse skin conditions and is not under any medication likely to interfere with the results.
- •8\) The subjects who have not done any facial treatment, or any herbal facial, tanning removal for more than 30 days and who regularly use tanning removal products.
- •9\) The subject is willing and able to follow the study directions, and participate in the study.
- •10\)The subject must be able to understand and provide written informed consent to participate in the study.
Exclusion Criteria
- •1\) Subject with known allergy or sensitization to product ingredients such as niacinamide, glycolic acid, Liquorice, vitamin c, mulberries, purple brazilian clay or any other ingredients.
- •2\) The subject had a facial or chemical peeling or derma abrasion \| roller etc. in the last 4 weeks.
- •3\) The subject has skin irritation, open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the face that can interfere with the reading.
- •4\) Be wearing any facial makeup, including false eyelashes, on the day of the study visit.
- •5\) Be using any skin lightening \| brightening or tanning removal product within 15 days and on the day of the study visit.
- •6\) Medication which may affect skin response and/or past medical history.
- •7\) The subject has a history of diabetes
- •8\) The subject has a history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
- •9\) The subject suffering from any active clinically significant skin diseases which may contraindicate.
- •10\) The subject has a history of any skin diseases including eczema, atopic dermatitis etc.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
N/A
Exploratory study for the efficacy and safety of Sansoninto on behavioral and psychological symptoms of dementia (BPSD) in patients with Dementia.: Multicenter trialDementia patients with BPSDJPRN-UMIN000021562Kanazawa University20
Completed
N/A
Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancercolorectal cancerJPRN-UMIN000001547Tsukuba Cancer Clinical Trial Group400
Completed
Phase 2
The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment.Thyroid cancerJPRN-UMIN000017777niversity of Tsukuba47
Completed
N/A
A clinical study to assess the safety and effectiveness of Anti-Gray Hair Product in Healthy Adult Human Subjects with Partially Gray HairCTRI/2023/01/048861Anveya Living Private Limited84
Not Yet Recruiting
N/A
A prospective study about efficacy and safety of selective arterial injection chemotherapy for ineffective or intorelable to the standard chemotherapy in advanced esophageal cancerEsophagusJPRN-UMIN000028542Showa University Koto Toyosu Hospital50